Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227602 · ClinicalTrials.gov registry record · NA
Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease
A NA study of Ulcerative Colitis and Crohn Disease, sponsored by Texas A&M University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02227602 is a NA study of Ulcerative Colitis and Crohn Disease that has completed, run by Texas A&M University. The registered enrollment target is 20 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02227602, a NA study of Ulcerative Colitis and Crohn Disease, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Bioactive compounds from mango are bioavailable and their anti-inflammatory efficacy has been demonstrated in animals and humans. However, the efficacy of mangoes has not previously been compared with respect to mild inflammatory bowel disease. In order to justify future pharmacokinetic and pharmacodynamic analyses in human clinical trials, a pilot assessment to determine efficacy in preventing or resolving Inflammatory bowel disease is a necessary step. Therefore, in this aim we will determine the clinical relevance of mango as an adjuvant treatment to conventional therapy in Inflammatory bowel disease . The effects of mango with common drug treatment in mild-moderate Inflammatory bowel disease will be compared to the drug-treatment alone. If mango or any other polyphenolic-rich food could be identified as helpful in shortening or reducing severity of episodes of inflammatory bowel disease, the addition of polyphenolics to conventional drug treatment in Inflammatory bowel disease would have a significant impact on public health.
Conditions Studied
Interventions
- DRUG Mango polyphenolics
Study Locations (1)
Texas
- Texas A&M University, Clinical Lab, Nutrition and Food Science Department - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227602
The ClinicalTrials.gov registry entry for NCT02227602 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (99% lower). The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Mango polyphenolics is the first listed.
NCT02227602 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02227602 about?
NCT02227602 is a clinical study titled "Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease". Bioactive compounds from mango are bioavailable and their anti-inflammatory efficacy has been demonstrated in animals and humans. However, the efficacy of mangoes has not previously been compared with respect to mild inflammatory bowel disease. In order to justify future pharmacokinetic and pharmaco...
What is the current status of trial NCT02227602?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-01. Estimated completion is 2018-03.
What conditions does trial NCT02227602 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease, Intestinal Diseases.
What interventions are being tested in trial NCT02227602?
The interventions under investigation include: Mango polyphenolics (DRUG).
Who is sponsoring clinical trial NCT02227602?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02227602 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
-
Fermented Food-Supplemented Diet in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.